<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38648458</article-id><article-id pub-id-type="pmc">PMC467005</article-id>
<article-id pub-id-type="publisher-id">IJO-72-501</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_2579_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Expression of CD44, PCNA and E-cadherin in pterygium tissues</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>Humeyra</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Turan</surname><given-names>Gulay</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Turan</surname><given-names>Meydan</given-names></name><xref rid="aff3" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff1">Department of Ophthalmology, Bal&#x00131;kesir University, Faculty of Medicine, Bal&#x00131;kesir, T&#x000fc;rkiye</aff><aff id="aff2"><label>1</label>Department of Pathology, Bal&#x00131;kesir University, Faculty of Medicine, Bal&#x00131;kesir, T&#x000fc;rkiye</aff><aff id="aff3"><label>2</label>Balikesir Ataturk C&#x00131;ty Hospital, Ophthalmology, Balikesir, T&#x000fc;rkiye</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Humeyra Y&#x00131;ld&#x00131;r&#x00131;m, Bal&#x00131;kesir Medical Faculty, &#x000c7;ag&#x00131;&#x0015f; Campus, 10145 Alt&#x00131;eyl&#x000fc;l, Bal&#x00131;kesir, T&#x000fc;rkiye. E-mail: <email xlink:href="balikesirhumeyra@gmail.com">balikesirhumeyra@gmail.com</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>4</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S501</fpage><lpage>S504</lpage><history><date date-type="received"><day>23</day><month>9</month><year>2023</year></date><date date-type="rev-recd"><day>18</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>07</day><month>2</month><year>2024</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>Pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. However, its pathogenesis remains unclear. This study aimed to determine the role of CD44, proliferating cell nuclear antigen (PCNA), and E-cadherin in pterygium formation and recurrence.</p></sec><sec id="st2"><title>Methods:</title><p>Sixty patients with pterygium participated in the study, and we collected conjunctival samples from 30 patients to form a control group. CD44, PCNA, and E-cadherin expressions in surgically excised pterygium were compared with tissue samples from the control group.</p></sec><sec id="st3"><title>Results:</title><p>We observed that the percentages of CD44 and PCNA were statistically higher in the primary pterygium group and recurrent pterygium group than in the control group (<italic toggle="yes">P</italic> &#x0003c; 0.001 and <italic toggle="yes">P</italic> &#x0003c; 0.001, respectively). Conversely, E-cadherin values were statistically higher in the control group than in the primary and recurrent pterygium groups (<italic toggle="yes">P</italic> = 0.013 and <italic toggle="yes">P</italic> &#x0003c; 0.001, respectively).</p></sec><sec id="st4"><title>Conclusion:</title><p>Cell proliferation and cell adhesion factors may play important roles in the pathogenesis of pterygium.</p></sec></abstract><kwd-group><kwd>CD44</kwd><kwd>E-cadherin</kwd><kwd>immunohistochemistry</kwd><kwd>PCNA</kwd><kwd>pterygium</kwd></kwd-group></article-meta></front><body><p>Pterygium is a common ocular surface disease defined by triangle-shaped fibrovascular conjunctival growth extending onto the cornea.[<xref rid="R1" ref-type="bibr">1</xref>] In severe cases, it may extend into the central cornea, inducing irregular corneal astigmatism and causing loss of vision.[<xref rid="R1" ref-type="bibr">1</xref>] The pterygium usually occurs nasally in the palpebral fissure, but it may also occur temporally or bilaterally. Although the pterygium&#x02019;s head is firmly attached to the cornea, its body is loosely attached to the bulbar conjunctiva.</p><p>The pathogenesis of pterygium has yet to be fully elucidated. The main etiological factor for pterygium development is ultraviolet light,[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref>] and the prevalence of pterygium increases toward the equator. The other causative factors suspected in the pathogenesis of pterygium include human papillomavirus infection, inflammation, chronic irritation, angiogenesis, lymphangiogenesis, and genetics.[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref><xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref>] Pterygium tissue resembles tumoral tissues in that it invades the cornea, recurs after resection, and exhibits cell proliferation. With the progression of pterygium, patients develop foreign body sensation, redness and itching due to inflammation, blurred vision, and astigmatism due to its progression to the corneal surface toward the optic axis.[<xref rid="R7" ref-type="bibr">7</xref>]</p><p>Surgical excision is the preferred treatment model for pterygium.[<xref rid="R8" ref-type="bibr">8</xref>] The bare sclera technique used in the past is no longer preferred because of its high recurrence rate. Conjunctival autograft, limbal autograft, amniotic membrane graft, and the use of antifibrotic agents are the preferred methods of treatment.[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R9" ref-type="bibr">9</xref>]</p><p>CD44 (phagocytic glycoprotein-1) is a member of a family of non-kinase, structurally changeable, and multifunctional transmembrane glycoproteins that are expressed to various extents in other cell types, including embryological stem cells, connective tissues, and bone marrow.[<xref rid="R10" ref-type="bibr">10</xref>] CD44 is involved in the organization of certain cellular processes, for instance, cell adhesion, division, and migration, by binding with its main ligand, hyaluronic acid.[<xref rid="R11" ref-type="bibr">11</xref>]</p><p>Proliferating cell nuclear antigen (PCNA) is a proliferation marker in the nucleus. PCNA plays a very important role in DNA synthesis, repair, and cell cycle regulation.[<xref rid="R12" ref-type="bibr">12</xref>] It is used as a proliferation marker in some cancer types.[<xref rid="R13" ref-type="bibr">13</xref>]</p><p>E-cadherin is a calcium-dependent transmembrane glycoprotein that plays a significant role in the protection of tissue integrity and cell-to-cell adhesion.[<xref rid="R1" ref-type="bibr">1</xref>] E-cadherin functions as a tumor suppressor protein by regulating cell activities.[<xref rid="R14" ref-type="bibr">14</xref>] Reduced expression of E-cadherin in many cancer types correlates with poor prognosis and the potential for metastasis.[<xref rid="R15" ref-type="bibr">15</xref><xref rid="R16" ref-type="bibr">16</xref>]</p><p>The present study aimed to investigate the expression patterns of CD44, PCNA, and E-cadherin in both control conjunctiva and pterygium tissue.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><p>Sixty patients with pterygium participated in the study. The pterygia patients were divided into primary and recurrent groups, and we collected conjunctival samples from 30 patients to use as a control group. Tan <italic toggle="yes">et al</italic>.[<xref rid="R17" ref-type="bibr">17</xref>] graded pterygium according to tissue transparency and classified it into three types by using the visibility of episcleral vessels as a sign of translucency. Type 2 pterygiums were included in the current study based on the grading system of Tan <italic toggle="yes">et al</italic>.[<xref rid="R17" ref-type="bibr">17</xref>]</p><p>The patients were informed about the surgical procedures to be performed and provided written consent. The research adhered to the ethical principles stated in the Declaration of Helsinki. Prior to commencing the study, the necessary approval was sought and obtained from the Clinical Research Ethics Committee of &#x02026;&#x02026; University Faculty of Medicine. Autograft pterygium surgery was performed under local anesthesia. The pterygium tissue was removed from the cornea surface, and an autograft was taken from the superior bulbar conjunctiva. The graft was then sutured with 8-0 Vicryl onto the scleral bed. During autograft pterygium surgery, conjunctival samples were collected from the upper temporal fornix region of the patients in the control group.</p><sec id="sec2-1"><title>Immunohistochemistry</title><p>The specimens were immersed in containers filled with 10% formalin and then embedded in paraffin. Thin sections measuring 4 &#x000b5;m were extracted from the samples and placed on glass slides with barcodes for identification. Following the process of deparaffinization and rehydration, the sections were subjected to histopathological evaluation through the use of hematoxylin and eosin staining.</p><p>We used primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings were reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV). At least 100 cells were counted, including immuno-positive cells, at a 20&#x000d7; magnification in three distinct microscopic areas of the pterygium tissue. The number of stained pixels reflects the intensity of staining of immunopositive cells and can be expressed as a percentage of the entire image pixel amount. The immunoreactivity level was evaluated based on the number of pixels, with fewer than 80 pixels indicating a weak (1+) reaction, 80&#x02013;200 pixels indicating moderate (2+) reactivity, and more than 200 pixels indicating strong (3+) reactivity. The positivity ratio was evaluated for CD44 and E-cadherin. For CD44, cytoplasmic staining was semi-quantitatively scored from 0 to 3+. For E-cadherin, cell membrane staining intensity was estimated as negative, weak, moderate, or strong.</p></sec><sec id="sec2-2"><title>Statistical analysis</title><p>For continuous variables, the data were presented as either the mean &#x000b1; standard deviation or the median with the range (minimum&#x02013;maximum) displayed. We conducted the Kolmogorov-Smirnov goodness-of-fit test to analyze the normality of the continuous variables. We employed one-way ANOVA to assess the variables that were found to be normally distributed between the three groups and the Kruskal-Wallis test for those that did not conform to normal distribution. Pairwise forward analyses (<italic toggle="yes">post hoc</italic>) were performed with the Bonferroni-corrected Mann-Whitney U test to determine in which group significance originated. The categorical variables were evaluated using the Chi-square test. The analyses were conducted using IBM SPSS version 26.0 (IBM Corporation, Armonk, NY, USA). Cases in which the Type 1 error level was below 5% were deemed statistically significant. A statistical significance level of <italic toggle="yes">P</italic> &#x0003c; 0.01 was accepted for the Bonferroni-corrected Mann-Whitney U test.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>Results</title><p>In the control group (group 1), we collected control conjunctiva from 30 patients (16 females and 14 males) with an age range of 48&#x02013;70 years (mean: 56.66 &#x000b1; 7.10 years). We collected primary pterygia from 30 patients (17 females and 13 males) aged 48&#x02013;72 years (mean: 59.13 &#x000b1; 7.43 years) (group 2) and collected recurrent pterygia from 30 patients (16 males and 14 females) aged 45&#x02013;73 years (mean: 59.06 &#x000b1; 7.37 years) (group 3). There were no notable variations observed between the groups regarding age and gender (<italic toggle="yes">P</italic> = 0.334 and <italic toggle="yes">P</italic> = 0.956, respectively).</p><p>We did, however, find significant differences in the percentage of CD44, E-cadherin, and PCNA between the groups (<italic toggle="yes">P</italic> &#x0003c; 0.001, <italic toggle="yes">P</italic> &#x0003c; 0.001, and <italic toggle="yes">P</italic> &#x0003c; 0.001, respectively). We observed that the CD44 and PCNA percentages were statistically higher (<italic toggle="yes">P</italic> &#x0003c; 0.001 and <italic toggle="yes">P</italic> &#x0003c; 0.001, respectively) in experimental groups 2 and 3 than in control group 1. Conversely, E-cadherin values were statistically higher in group 1 than in groups 2 and 3 (<italic toggle="yes">P</italic> = 0.013 and <italic toggle="yes">P</italic> &#x0003c; 0.001, respectively). We also determined that the CD44, E-cadherin, and PCNA percentages (<italic toggle="yes">P</italic> = 0.022, <italic toggle="yes">P</italic> = 0.025, and <italic toggle="yes">P</italic> = 0.074, respectively) were not statistically significantly different between group 2 and group 3 [<xref rid="IJO.IJO_2579_23-T1" ref-type="table">Table 1</xref>, <xref rid="IJO.IJO_2579_23-F1" ref-type="fig">Figs. 1</xref>&#x02013;<xref rid="IJO.IJO_2579_23-F3" ref-type="fig">3</xref>].</p><fig position="float" id="IJO.IJO_2579_23-F1"><label>Figure 1</label><caption><p>(a) At a magnification of 400&#x000d7;, the expression of PCNA can be observed in the nucleus of healthy conjunctival epithelial cells. (b) This is an image of primary pterygium tissue, showing the expression of PCNA in the nuclei of epithelial cells. The image was magnified to 200&#x000d7;. (c) At a magnification of 400&#x000d7;, it was observed that PCNA was expressed in the nuclei of epithelial cells in recurrent pterygium tissue</p></caption><graphic xlink:href="IJO-72-501-g001" position="float"/></fig><fig position="float" id="IJO.IJO_2579_23-F2"><label>Figure 2</label><caption><p>(a) CD44 is expressed on epithelial and stromal cells in normal bulbar conjunctiva (score 1) observed under 400 &#x000d7; magnification. (b) CD44 is expressed in both epithelial and stromal cells in primary pterygium (score 2, light brown) at a magnification of 400&#x000d7;. (c) CD44 is expressed in both epithelial and stromal cells of recurrent pterygium, shown as dark brown color and scored 3 at a magnification of 400&#x000d7;</p></caption><graphic xlink:href="IJO-72-501-g002" position="float"/></fig><fig position="float" id="IJO.IJO_2579_23-F3"><label>Figure 3</label><caption><p>(a) E-cadherin is expressed in normal bulbar conjunctiva epithelial cells (score 3, dark brown, 400&#x000d7;). (b) The expression level of e-cadherin in primary pterygium epithelial cells is scored at 2, appearing as a light brown color when viewed at 400&#x000d7; magnification. (c) Expression of e-cadherin was scored 1 in light brown recurrent pterygium in both epithelial and stromal cells, observed at 400&#x000d7; magnification</p></caption><graphic xlink:href="IJO-72-501-g003" position="float"/></fig><table-wrap position="float" id="IJO.IJO_2579_23-T1"><label>Table 1</label><caption><p>Comparison of age, gender, and CD44, E-cadherin, and PCNA percentage values between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 1 (<italic toggle="yes">n</italic>=30)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 2 (<italic toggle="yes">n</italic>=30)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 3 (<italic toggle="yes">n</italic>=30)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">56.66&#x000b1;7.10</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">59.13&#x000b1;7.43</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">59.06&#x000b1;7.37</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.334*</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (f/m)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16/14</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17/13</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16/14</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.956**</td></tr><tr><td align="left" rowspan="1" colspan="1">CD44</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0 (0&#x02013;1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (1&#x02013;2)<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.5 (1&#x02013;3)<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001***</td></tr><tr><td align="left" rowspan="1" colspan="1">E-cadherin</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (0&#x02013;3)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (0&#x02013;2)<sup>b</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (0&#x02013;2)<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001***</td></tr><tr><td align="left" rowspan="1" colspan="1">PCNA %</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (0&#x02013;5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 (5&#x02013;51)<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15 (1&#x02013;54)<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001***</td></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p>*One-way ANOVA. **Chi-square test. ***Kruskal-Wallis test (<italic toggle="yes">post hoc</italic>: Bonferroni-corrected Mann Whitney <italic toggle="yes">U</italic> test, <sup>a</sup><italic toggle="yes">P</italic>&#x0003c;0.001 vs. group 1, <sup>b</sup><italic toggle="yes">P</italic>=0.013 vs. group 1)</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>This study examined the levels of PCNA, CD44, and E-cadherin in pterygium tissue samples and control conjunctiva. Our results indicated a significant increase in positive PCNA and CD44 rates in the pterygium samples, while the E-cadherin level was significantly lower than in control conjunctival tissue samples. These findings suggest that cell proliferation and loss of cell adhesion are involved in the pathogenesis of pterygium, a disease with tumor-like growth characteristics.[<xref rid="R6" ref-type="bibr">6</xref>]</p><p>Despite being considered benign, pterygium exhibits properties similar to metastatic tissues, including dense cell proliferation, inflammation, cell migration, local angiogenesis, and epithelial-mesenchymal transition.[<xref rid="R18" ref-type="bibr">18</xref><xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref>] Our research also revealed a lower amount of E-cadherin in pterygium tissues than in control conjunctival tissue. Moreover, we observed no notable difference in E-cadherin levels between primary and recurrent pterygium cases. E-cadherin plays a crucial role in cell adhesion between epithelial cells, and its decreased expression can lead to tumor growth and proliferation, ultimately leading to metastasis.[<xref rid="R21" ref-type="bibr">21</xref>] Several studies have shown that low E-cadherin expression increases tumor progression in some types of cancer.[<xref rid="R22" ref-type="bibr">22</xref><xref rid="R23" ref-type="bibr">23</xref>]</p><p>PCNA is a protein associated with cell proliferation and is used as a tumor marker for some types of cancer.[<xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref><xref rid="R26" ref-type="bibr">26</xref>] Our study found that PCNA expression was significantly higher in pterygium samples than in control conjunctiva samples.[<xref rid="R27" ref-type="bibr">27</xref>] Cell proliferation plays a vital role in the pathogenesis of pterygium. In the study by Liang <italic toggle="yes">et al</italic>.,[<xref rid="R27" ref-type="bibr">27</xref>] the rates of PCNA and nuclear protein ki-67, another proliferation marker, were higher in pterygium tissue than in normal conjunctiva. PCNA was detected 72.7% in pterygium tissue and 30.4% in normal conjunctival tissue. Studies have shown that ki-67, an important component of the cell cycle, is more abundant in pterygium tissue than in normal conjunctival tissue.[<xref rid="R28" ref-type="bibr">28</xref><xref rid="R29" ref-type="bibr">29</xref>]</p><p>Similarly, CD44 is a protein that regulates cellular processes such as cell division, adhesion, and migration.[<xref rid="R10" ref-type="bibr">10</xref>] Aside from its usual cellular roles, CD44 has been identified as a significant indicator of the presence of cancer stem cells.[<xref rid="R30" ref-type="bibr">30</xref><xref rid="R31" ref-type="bibr">31</xref>] Studies have shown that CD44 contributes to tumor invasion and metastasis by promoting the adhesion of tumor cells to endothelial and fibronectin-enriched matrices.[<xref rid="R32" ref-type="bibr">32</xref><xref rid="R33" ref-type="bibr">33</xref>]</p><p>The present study had some limitations. As it was not considered ethically appropriate to take conjunctival samples from healthy eyes, we took the control group from the superior bulbar conjunctiva of eyes with pterygium. Another limitation is the small number of cases.</p></sec><sec sec-type="conclusion" id="sec1-4"><title>Conclusion</title><p>In conclusion, our research provides valuable insights into the pathogenesis of pterygium and the roles of PCNA, CD44, and E-cadherin in this disease. These findings can potentially be used to develop new therapeutic strategies to treat pterygium and prevent relapses.</p><sec sec-type="funding-statement" id="sec2-3"><title>Financial support and sponsorship</title><p>The study was supported by the Scientific Investigations Foundation of Balikesir University (Project No: 2021/061). The research adhered to the ethical principles stated in the Declaration of Helsinki. Prior to commencing the study, the necessary approval was sought and obtained from the Clinical Research Ethics Committee of Bal&#x00131;kesir University Faculty of Medicine.</p></sec><sec sec-type="COI-statement" id="sec2-4"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>A</given-names></name>
<name><surname>Stern</surname><given-names>G</given-names></name></person-group><article-title>Correlation between pterygium size and induced corneal astigmatism</article-title><source>Cornea</source><year>1998</year><volume>17</volume><fpage>28</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">9436877</pub-id>
</element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>T</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Xie</surname><given-names>L</given-names></name>
<name><surname>He</surname><given-names>X</given-names></name>
<name><surname>Bai</surname><given-names>J</given-names></name></person-group><article-title>Progress in the pathogenesis of pterygium</article-title><source>Curr Eye Res</source><year>2013</year><volume>38</volume><fpage>1191</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24047084</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palewski</surname><given-names>M</given-names></name>
<name><surname>Budnik</surname><given-names>A</given-names></name>
<name><surname>Konopi&#x00144;ska</surname><given-names>J</given-names></name></person-group><article-title>Evaluating the efficacy and safety of different pterygium surgeries: A review of the literature</article-title><source>Int J Environ Res Public Health</source><year>2022</year><volume>19</volume><fpage>11357</fpage><pub-id pub-id-type="pmid">36141628</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>C&#x000e1;rdenas-Cant&#x000fa;</surname><given-names>E</given-names></name>
<name><surname>Zavala</surname><given-names>J</given-names></name>
<name><surname>Valenzuela</surname><given-names>J</given-names></name>
<name><surname>Valdez-Garc&#x000ed;a</surname><given-names>JE</given-names></name></person-group><article-title>Molecular basis of pterygium development</article-title><source>Semin Ophthalmol</source><year>2016</year><volume>31</volume><fpage>567</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">25415268</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Girolamo</surname><given-names>N</given-names></name>
<name><surname>Chui</surname><given-names>J</given-names></name>
<name><surname>Coroneo</surname><given-names>MT</given-names></name>
<name><surname>Wakefield</surname><given-names>D</given-names></name></person-group><article-title>Pathogenesis of pterygia: Role of cytokines, growth factors, and matrix metalloproteinases</article-title><source>Progr Retin Eye Res</source><year>2004</year><volume>23</volume><fpage>195</fpage><lpage>228</lpage></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anguria</surname><given-names>P</given-names></name>
<name><surname>Kitinya</surname><given-names>J</given-names></name>
<name><surname>Ntuli</surname><given-names>S</given-names></name>
<name><surname>Carmichael</surname><given-names>T</given-names></name></person-group><article-title>The role of heredity in pterygium development</article-title><source>Int J Ophthalmol</source><year>2014</year><volume>7</volume><fpage>563</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">24967209</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linaburg</surname><given-names>T</given-names></name>
<name><surname>Choi</surname><given-names>D</given-names></name>
<name><surname>Bunya</surname><given-names>VY</given-names></name>
<name><surname>Massaro-Giordano</surname><given-names>M</given-names></name>
<name><surname>Brice&#x000f1;o</surname><given-names>CA</given-names></name></person-group><article-title>Systematic review: The effects of pterygium and pingueculum on the ocular surface and the efficacy of surgical excision</article-title><source>Cornea</source><year>2021</year><volume>40</volume><fpage>258</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">33156079</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nuzzi</surname><given-names>R</given-names></name>
<name><surname>Tridico</surname><given-names>F</given-names></name></person-group><article-title>How to minimize pterygium recurrence rates: Clinical perspectives</article-title><source>Clin Ophthalmol</source><year>2018</year><volume>12</volume><fpage>2347</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">30538417</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al Fayez</surname><given-names>MF</given-names></name></person-group><article-title>Limbal-conjunctival vs conjunctival autograft transplant for recurrent pterygia: A prospective randomized controlled trial</article-title><source>JAMA Ophthalmol</source><year>2013</year><volume>131</volume><fpage>11</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">23307203</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Naor</surname><given-names>D</given-names></name>
<name><surname>Sionov</surname><given-names>RV</given-names></name>
<name><surname>Ish-Shalom</surname><given-names>D</given-names></name></person-group><article-title>CD44: Structure, function and association with the malignant process</article-title><person-group person-group-type="editor">
<name><surname>Vande</surname><given-names>Woude GF</given-names></name>
<name><surname>Klein</surname><given-names>G</given-names></name></person-group><source>Advances in Cancer Research</source><volume>71</volume><publisher-loc>San Diego</publisher-loc><publisher-name>Academic Press</publisher-name><year>1997</year><fpage>241</fpage><lpage>319</lpage></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodison</surname><given-names>S</given-names></name>
<name><surname>Urquidi</surname><given-names>V</given-names></name>
<name><surname>Tarin</surname><given-names>D</given-names></name></person-group><article-title>CD44 cell adhesion molecules</article-title><source>Mol Pathol</source><year>1999</year><volume>51</volume><fpage>189</fpage><lpage>96</lpage></element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelman</surname><given-names>Z</given-names></name></person-group><article-title>PCNA: Structure, functions and interactions</article-title><source>Oncogene</source><year>1997</year><volume>14</volume><fpage>629</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9038370</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stuart-Harris</surname><given-names>R</given-names></name>
<name><surname>Caldas</surname><given-names>C</given-names></name>
<name><surname>Pinder</surname><given-names>SE</given-names></name>
<name><surname>Pharoah</surname><given-names>P</given-names></name></person-group><article-title>Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients</article-title><source>Breast</source><year>2008</year><volume>17</volume><fpage>323</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18455396</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Semb</surname><given-names>H</given-names></name>
<name><surname>Christofori</surname><given-names>G</given-names></name></person-group><article-title>The tumor-suppressor function of E-cadherin</article-title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>1588</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">9837810</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z</given-names></name>
<name><surname>Yin</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Liu</surname><given-names>W</given-names></name>
<name><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>Prognostic value of reduced E-cadherin expression in breast cancer: A meta-analysis</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>16445</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">28147315</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaszak</surname><given-names>I</given-names></name>
<name><surname>Witkowska-Pi&#x00142;aszewicz</surname><given-names>O</given-names></name>
<name><surname>Niewiadomska</surname><given-names>Z</given-names></name>
<name><surname>Dworecka-Kaszak</surname><given-names>B</given-names></name>
<name><surname>Ngosa Toka</surname><given-names>F</given-names></name>
<name><surname>Jurka</surname><given-names>P</given-names></name></person-group><article-title>Role of cadherins in cancer&#x02014;A review</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>7624</fpage><pub-id pub-id-type="pmid">33076339</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>DT</given-names></name>
<name><surname>Chee</surname><given-names>SP</given-names></name>
<name><surname>Dear</surname><given-names>KB</given-names></name>
<name><surname>Lim</surname><given-names>AS</given-names></name></person-group><article-title>Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision</article-title><source>Arch Ophthalmol</source><year>1997</year><volume>115</volume><fpage>1235</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9338666</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loh</surname><given-names>C-Y</given-names></name>
<name><surname>Chai</surname><given-names>JY</given-names></name>
<name><surname>Tang</surname><given-names>TF</given-names></name>
<name><surname>Wong</surname><given-names>WF</given-names></name>
<name><surname>Sethi</surname><given-names>G</given-names></name>
<name><surname>Shanmugam</surname><given-names>MK</given-names></name>
<etal/></person-group><article-title>The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges</article-title><source>Cells</source><year>2019</year><volume>8</volume><fpage>1118</fpage><pub-id pub-id-type="pmid">31547193</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kato</surname><given-names>N</given-names></name>
<name><surname>Shimmura</surname><given-names>S</given-names></name>
<name><surname>Kawakita</surname><given-names>T</given-names></name>
<name><surname>Miyashita</surname><given-names>H</given-names></name>
<name><surname>Ogawa</surname><given-names>Y</given-names></name>
<name><surname>Yoshida</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>&#x003b2;-Catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium</article-title><source>Invest Ophthalmol Vis Sci</source><year>2007</year><volume>48</volume><fpage>1511</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17389479</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dongre</surname><given-names>A</given-names></name>
<name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer</article-title><source>Nat Rev Mol Cell Biol</source><year>2019</year><volume>20</volume><fpage>69</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">30459476</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Umbas</surname><given-names>R</given-names></name>
<name><surname>Isaacs</surname><given-names>WB</given-names></name>
<name><surname>Bringuier</surname><given-names>PP</given-names></name>
<name><surname>Schaafsma</surname><given-names>E</given-names></name>
<name><surname>Karthaus</surname><given-names>HFM</given-names></name>
<name><surname>Gosse</surname><given-names>ON</given-names></name>
<etal/></person-group><article-title>Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>3929</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">7518346</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kase</surname><given-names>S</given-names></name>
<name><surname>Sugio</surname><given-names>K</given-names></name>
<name><surname>Yamazaki</surname><given-names>K</given-names></name>
<name><surname>Okamoto</surname><given-names>T</given-names></name>
<name><surname>Yano</surname><given-names>T</given-names></name>
<name><surname>Sugimachi</surname><given-names>K</given-names></name></person-group><article-title>Expression of E-cadherin and &#x003b2;-catenin in human non-small cell lung cancer and the clinical significance</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>4789</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11156236</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>Z</given-names></name>
<name><surname>Jia</surname><given-names>M</given-names></name>
<name><surname>Zhao</surname><given-names>X</given-names></name></person-group><article-title>Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: Evidence from meta-analysis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e70858</fpage><pub-id pub-id-type="pmid">23923027</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Y</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
<name><surname>Yu</surname><given-names>S</given-names></name>
<name><surname>Han</surname><given-names>Y</given-names></name>
<name><surname>Kank</surname><given-names>K</given-names></name>
<name><surname>Xu</surname><given-names>H</given-names></name>
<etal/></person-group><article-title>GTSE1, CDC20, PCNA, and MCM6 synergistically affect regulations in cell cycle and indicate poor prognosis in liver cancer</article-title><source>Anal Cell Pathol (Amst)</source><year>2019</year><volume>2019</volume><fpage>1038069</fpage><pub-id pub-id-type="pmid">32082966</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>EMC</given-names></name>
<name><surname>Ratnayake</surname><given-names>J</given-names></name>
<name><surname>Rich</surname><given-names>AM</given-names></name></person-group><article-title>Assessment of proliferating cell nuclear antigen (PCNA) expression at the invading front of oral squamous cell carcinoma</article-title><source>BMC Oral Health</source><year>2019</year><volume>19</volume><fpage>233</fpage><pub-id pub-id-type="pmid">31672124</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guzi&#x00144;ska-Ustymowicz</surname><given-names>K</given-names></name>
<name><surname>Pryczynicz</surname><given-names>A</given-names></name>
<name><surname>Kemona</surname><given-names>A</given-names></name>
<name><surname>Czy&#x0017c;ewska</surname><given-names>J</given-names></name></person-group><article-title>Correlation between proliferation markers: PCNA, Ki-67, MCM&#x02013;2 and antiapoptotic protein Bcl-2 in colorectal cancer</article-title><source>Anticancer Res</source><year>2009</year><volume>29</volume><fpage>3049</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">19661314</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>K</given-names></name>
<name><surname>Jiang</surname><given-names>Z</given-names></name>
<name><surname>Ding</surname><given-names>B</given-names></name>
<name><surname>Cheng</surname><given-names>P</given-names></name>
<name><surname>Huang</surname><given-names>D</given-names></name>
<name><surname>Tao</surname><given-names>L</given-names></name></person-group><article-title>Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva</article-title><source>Mol Vis</source><year>2011</year><volume>17</volume><fpage>1687</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">21738398</pub-id>
</element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kase</surname><given-names>S</given-names></name>
<name><surname>Takahashi</surname><given-names>S</given-names></name>
<name><surname>Sato</surname><given-names>I</given-names></name>
<name><surname>Nakanishi</surname><given-names>K</given-names></name>
<name><surname>Yoshida</surname><given-names>K</given-names></name>
<name><surname>Ohno</surname><given-names>S</given-names></name></person-group><article-title>Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium</article-title><source>Br J Ophthalmol</source><year>2007</year><volume>91</volume><fpage>958</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17179165</pub-id>
</element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turan</surname><given-names>M</given-names></name>
<name><surname>Turan</surname><given-names>G</given-names></name></person-group><article-title>Bcl-2, p53, and Ki-67 expression in pterygium and normal conjunctiva and their relationship with pterygium recurrence</article-title><source>Eur J Ophthalmol</source><year>2020</year><volume>30</volume><fpage>1232</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">32703006</pub-id>
</element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bellizzi</surname><given-names>A</given-names></name>
<name><surname>Sebastian</surname><given-names>S</given-names></name>
<name><surname>Ceglia</surname><given-names>P</given-names></name>
<name><surname>Centonze</surname><given-names>M</given-names></name>
<name><surname>Divella</surname><given-names>R</given-names></name>
<name><surname>Manzillo</surname><given-names>EF</given-names></name>
<etal/></person-group><article-title>Co-expression of CD133+/CD44+in human colon cancer and liver metastasis</article-title><source>J Cell Physiol</source><year>2013</year><volume>228</volume><fpage>408</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22740326</pub-id>
</element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Z</given-names></name>
<name><surname>Hao</surname><given-names>X</given-names></name>
<name><surname>Yan</surname><given-names>M</given-names></name>
<name><surname>Yao</surname><given-names>M</given-names></name>
<name><surname>Ge</surname><given-names>C</given-names></name>
<name><surname>Gu</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Cancer stem/progenitor cells are highly enriched in CD133+CD44+population in hepatocellular carcinoma</article-title><source>Int J Cancer</source><year>2010</year><volume>126</volume><fpage>2067</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">19711346</pub-id>
</element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Fu</surname><given-names>Z</given-names></name>
<name><surname>Xu</surname><given-names>S</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>P</given-names></name></person-group><article-title>The prognostic value of CD44 expression in gastric cancer: A meta-analysis</article-title><source>Biomed Pharmacother</source><year>2014</year><volume>68</volume><fpage>693</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25194445</pub-id>
</element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Tang</surname><given-names>Y</given-names></name>
<name><surname>Xie</surname><given-names>L</given-names></name>
<name><surname>Huang</surname><given-names>A</given-names></name>
<name><surname>Xue</surname><given-names>C</given-names></name>
<name><surname>Gu</surname><given-names>Z</given-names></name>
<etal/></person-group><article-title>The prognostic and clinical value of CD44 in colorectal cancer: A meta-analysis</article-title><source>Front Oncol</source><year>2019</year><volume>9</volume><fpage>309</fpage><pub-id pub-id-type="pmid">31114754</pub-id>
</element-citation></ref></ref-list></back></article>